Recursion Pharmaceuticals has announced the enrollment of the first CCM patient in Phase 2 of their REC-994 trial. This is the first industry-sponsored trial of a medicine for cerebral cavernous malformations., a huge milestone in the path toward better treatments.
Trial information (will be updated shortly with trial site locations as these become available)